CDK9 inhibitor LDC000067 treatment significantly suppressed HFD-induced inflammation, cell proliferation and phenotypic switching of VSMCs resulting in reduced atherosclerosis in the ApoE-/- mice, which were further confirmed in vitro using ox-LDL-treated human VSMCs. The gene discussed is CDK9; the disease is atherosclerosis.